Us Health Dept Of Health & Human Services Clinic/Center - Public Health, Federal Medicare: Not Enrolled in Medicare Practice Location: Black Coal Drive, #29, Fort Washakie, WY 82514 Phone: 307-332-7300 Fax: 307-332-7464 |
Wind River Service Unit Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Not Enrolled in Medicare Practice Location: Bldg. 29 Black Coal Drive, Fort Washakie, WY 82514 Phone: 307-332-7300 Fax: 307-332-3931 |
Wind River Health Center Clinic/Center Medicare: Not Enrolled in Medicare Practice Location: 29 Black Coal Drive, Fort Washakie, WY 82514 Phone: 307-332-0446 Fax: 307-332-0131 |
Phs Indian Health Service Clinic/Center - Public Health, Federal Medicare: Not Enrolled in Medicare Practice Location: 29 Black Coal Drive, Fort Washakie, WY 82514 Phone: 307-332-7300 Fax: 307-332-5753 |
News Archive
In the presentation, Damian Marron will provide an overview of TxCell and its personalized T cell immunotherapy platform ASTrIA. Additional details will also be provided to institutional investors in one on one meetings at the conference.
ThermoGenesis Corp., a leading supplier of innovative products for processing and storing adult stem cells, said today its Res-Q(TM) 60 BMC ("Res-Q") System has demonstrated positive outcomes in its initial applications, according to its orthopedic distribution partner Celling Technologies, a subsidiary of SpineSmith, LLC.
Results of a study presented at the AACR 102nd Annual Meeting 2011, held here April 2-6, lend credence to the idea that improving quality of life affects stress-related biological markers and possibly the health of people with cancer.
The new treatment involves injecting thousands of the beads via an incision into the hepatic artery - the main blood supply for the liver. When the microspheres are injected they are picked up by the blood flow and eventually lodge in the malignant cells of the tumours.
In a comparison of two blood-thinning medications, heparin was associated with significantly fewer major cardiovascular events at 28 days than bivalirudin in patients receiving primary percutaneous coronary intervention after a heart attack, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.
› Verified 8 days ago